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Abstract: The advent of ‘incretin‑based therapies’ – GLP‑1 agonists and dipeptidyl‑peptidase‑4 
inhibitors – which result in improvements in glycemic control comparable to those with existing 
oral hypoglycemic agents, and potentially improve cardiovascular and pancreatic β‑cell function, 
represents a major therapeutic advance in the management of type 2 diabetes. Gastrointestinal 
adverse effects occur commonly with GLP‑1 agonists, and rarely with DPP‑4 inhibitors, but are 
dose‑dependent and usually transient. The low risk of hypoglycemia, and beneficial or neutral 
effects on body weight, render GLP‑1 agonists and DPP‑4 inhibitors suitable alternatives to 
insulin secretagogues and insulin in overweight and elderly patients. Incretin‑based therapies 
also improve quality of life in patients with type 2 diabetes, and may be cost‑effective in the 
long term.
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Introduction
Type 2 diabetes mellitus (T2DM) is well‑recognized as a major problem worldwide, 
with substantial impacts on morbidity, mortality, quality of life, and health care 
costs. Because current treatment regimens for T2DM do not effectively target the 
fundamental defects in glucose‑mediated insulin secretion and beta‑cell loss, an 
increasing proportion of T2DM patients progress to requiring insulin. Accordingly, 
the recent advent of so‑called ‘incretin‑based therapies’, the incretin hormones being 
glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic peptide (GIP), 
which have the potential to address these defects, represents a major paradigm shift 
in management.
The prevalence of T2DM has been rising dramatically, reflecting aging populations 
and the increasing prevalence of obesity, so that by 2025 an estimated 350 million 
people worldwide will be affected.1 T2DM is characterized by peripheral insulin 
resistance, impaired regulation of hepatic glucose production, and declining β‑cell 
function. The last is evident initially as impaired first‑phase insulin secretion in 
response to oral, or intravenous, glucose and progresses at a variable rate to abso‑
lute insulin deficiency, reflecting β‑cell failure, which is present in a substantial 
number of T2DM patients at diagnosis. This defect, rather than insulin resistance, 
may be a primary abnormality in T2DM, particularly in Asian populations, in which 
postprandial hyperglycemia is often apparent before elevation of fasting plasma 
glucose.1 The development, and progression, of the macrovascular (cardiovascular, 
cerebrovascular and peripheral vascular disease) and, particularly, microvascular Therapeutics and Clinical Risk Management 2009:5 684
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(nephropathy, neuropathy, retinopathy) complications of 
diabetes can be reduced substantially by optimizing glycemic 
control.2,3 However, many patients fail to achieve the target 
glycated hemoglobin (HbA1c) of 7% suggested by the 
American Diabetes Association and European Association 
for the Study of Diabetes, despite use of maximal doses 
of oral hypoglycemic agents (OHAs) in combination.4 
Moreover, concerns have recently been raised over the risk 
of malignancy, particularly breast cancer, with the use of 
sulfonylureas and insulin (especially glargine).5
Current therapy for type 2 diabetes
The majority of OHAs in common use are insulin sensitizers 
and/or insulin secretagogues. Older patients, in particular, 
are vulnerable to impaired awareness of hypoglycemia with 
consequent neuroglycopenia and adverse cardiovascular 
effects, dictating the need for particular caution with therapies 
that increase the risk of hypoglycemia. A history of severe 
hypoglycemia in older T2DM patients has been associated 
with a greater risk of dementia, which increases with the 
number of hypoglycemic episodes.6 There has been consider‑
able interest in the outcomes of the recent ADVANCE7 and 
ACCORD8 trials, which failed to show any cardiovascular 
benefit of lowering HbA1c to below 7% in patients recently 
diagnosed with T2DM. Significantly, in the ACCORD trial, 
combination therapy using high doses of thiazolidinediones 
(TZD), sulfonylureas (SU), metformin, and insulin, was 
associated with an increase in cardiovascular and all‑cause 
mortality, possibly because of hypoglycemia. Metformin 
and TZDs decrease insulin resistance and hepatic glucose 
output, but are contraindicated in patients with significant 
renal and/or cardiac dysfunction, both of which occur fre‑
quently in T2DM.
There is now compelling evidence that postprandial 
hyperglycemia (PPG) is a dominant contributor to overall 
glycemia, particularly when HbA1c is below 8.5%,9 and that 
PPG increases cardiovascular risk.10,11 However, no current 
OHA specifically targets PPG, with the possible excep‑
tion of α‑glucosidase inhibitors such as acarbose, which 
decrease the rate of glucose absorption, but whose use is 
limited by a high prevalence of gastrointestinal adverse 
effects (GI AEs); and the meglitinides repaglinide and 
nateglinide, which are insulin secretagogues (though the 
risk of hypoglycemia is lower than that with sulfonylureas). 
Furthermore, higher doses, and combinations, of OHA 
are progressively required in the majority of patients.4 
The reasons for this are diverse and include difficulty in 
compliance with lifestyle modifications (diet, exercise) and 
medications; but perhaps, most importantly, the failure of 
these OHAs to target several underlying pathophysiologic 
mechanisms of T2DM, particularly inappropriately high 
glucagon secretion, impaired first‑phase insulin secretion, 
and progressive β‑cell failure. Hence, the availability of 
drugs that stimulate insulin secretion in a physiological 
fashion, ie, at elevated glucose levels but not during eugly‑
cemia, are weight‑neutral or promote weight loss, and have 
beneficial effects to preserve β‑cell function, would represent 
a major asset in the management of T2DM. These properties 
are evident with recently developed medications that target 
the incretin system, namely the glucagon‑like peptide‑1 
agonists and the dipeptidyl peptidase‑IV inhibitors, which 
form the major focus of the review.
The incretin effect – implications  
for pathophysiology and management 
of  T2DM
Subsequent to the discovery of insulin, La Barre reported in 
1932 that a substance produced in the upper intestine had the 
capacity to cause hypoglycemia without stimulating exocrine 
pancreatic secretion, which he termed ‘incrétine’ (incretin), 
and envisaged its use for the treatment of diabetes.12 However, 
more than three decades would elapse before the ‘incretin 
effect’, ie, greater insulin release in response to an oral glucose 
load than an isoglycemic intravenous infusion, was demon‑
strated in 1964 by concurrent reports from both sides of the 
Atlantic.13,14 The known incretin hormones, glucose‑dependent 
insulinotropic polypeptide(GIP), a 42‑amino acid hormone 
produced by K‑cells in the proximal small intestine, and 
glucagon‑like peptide‑1 (GLP‑1), a 30‑amino acid peptide 
synthesized and secreted by L‑cells in the ileum and colon, 
were not isolated until 197015 and 1985,16 respectively.
In healthy people, up to 70% of post‑glucose insulin 
secretion is mediated by incretins.17 However, in T2DM 
patients, the insulin response to oral glucose is blunted in 
comparison to non‑diabetic control subjects,18 suggesting 
impairment of the incretin effect. The actions of incretins 
on the defects in glucose metabolism, pancreatic func‑
tion and energy intake in T2DM patients are shown in 
Table 1. In T2DM patients during hyperglycemic clamp 
studies, infusion of GLP‑1, but not GIP, stimulates insulin 
secretion,19 establishing that the insulinotropic effect of 
GLP‑1 is relatively well‑preserved in T2DM, despite possibly 
lower levels, when compared to non‑diabetic subjects.20 
On the other hand, GIP levels are essentially normal in 
T2DM but GIP‑stimulated second‑phase insulin secretion is Therapeutics and Clinical Risk Management 2009:5 685
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markedly diminshed21 (although it has recently been reported 
that reversal of poor glycemic control in T2DM improves 
the insulin response to both GIP and GLP‑1).21 Hence, the 
development of incretin‑based therapies for T2DM has 
hitherto focused on GLP‑1, rather than GIP.
In both T2DM and healthy humans, circulating levels 
of intact GLP‑1 decrease rapidly (half‑life ∼2 minutes) 
due to inactivation by the enzyme, dipeptidyl peptide‑4 
(DPP‑4), such that biologically active GLP‑1 represents 
only 10% to 20% of total plasma levels.22 Among the 
truncated forms of GLP‑1, GLP‑1 (7–36) was found to 
be more potent compared to other metabolites, such as 
the 9–36 form.23 The secretion of GLP‑1 depends on the 
rate of delivery of carbohydrate to the small intestine, and 
is thus influenced by the rate of gastric emptying.24 GLP‑1 
activates specific G‑protein‑coupled receptors on β‑cells to 
stimulate insulin secretion at a threshold glucose concentra‑
tion of 3.7 mmol/L, and also reduces glucose‑dependent 
glucagon secretion, possibly in a paracrine fashion by insulin, 
or via GLP‑1 receptors on α‑cells,25 although the precise 
mechanism for glucagon suppression is unknown. The role 
of endogenous GLP‑1 in glucoregulation was established by 
animal and human studies – GLP‑1‑receptor knockout mice 
display impaired glucose tolerance and glucose‑stimulated 
insulin secretion.26 Administration of the GLP‑1 receptor 
antagonist, exendin (9–39), inhibited postprandial insulin 
secretion and concomitantly increased plasma glucose in 
mice,27 and accelerated gastric emptying in rats.28 Similarly, 
treatment of non‑diabetic human subjects with exendin 9–39 
results in defective glucose‑stimulated insulin secretion, 
reduced glucose uptake, increased glucagon levels, and, 
possibly, accelerated gastric emptying.29–31 Slowing of gastric 
emptying may be as, if not more, important for postpran‑
dial glycemic control than stimulating insulin, given that 
variations in gastric emptying account for about 35% of the 
variance in the glycemic response to 75 g oral glucose loads in 
healthy subjects,32 as well as T2DM patients.33 The relation‑
ship of glycemia with gastric emptying is also evident for the 
ingestion of solid carbohydrate‑containing food.34,35
Exogenous GLP‑1 has diverse effects on pancreatic 
endocrine function and gut motility. Importantly, it has 
no significant insulinotropic effects below a glucose thresh‑
old ∼4 mmol/L,36 and the counterregulatory release of glucagon 
in response to hypoglycemia is preserved, even when GLP‑1 is 
administered. Exogenous GLP‑1 also stimulates insulin gene 
transcription and other steps in insulin biosynthesis,37 and, in 
in vitro studies, has a trophic effect on β‑cells by increasing 
proliferation and neogenesis, and inhibiting apoptosis,38,39 
which has the potential to retard or reverse β‑cell failure, 
the fundamental defect in T2DM. In rats, GLP‑1 infusion 
has been reported to increase insulin secretion in response 
to feeding, and reduce glucagon release and postprandial 
glycemia.40 Exogenous GLP‑1 has also been shown to inhibit 
energy intake and gastric emptying in rats.41 In humans with 
T2DM, overnight GLP‑1 infusions lowered blood glucose by 
restoring first‑phase insulin secretion and improving β‑cell 
function to levels that were comparable to non‑diabetic 
subjects.42 Preprandial boluses of GLP‑1 were also effective 
in improving postprandial glucose levels.43 Administration 
of exogenous GLP‑1, resulting in supraphysiological levels 
in peripheral blood, stimulated glucose‑mediated insulin 
secretion while suppressing glucagon and gastric emptying 
in T2DM patients with poor glycemic control.44 In contrast, 
the insulin response to a carbohydrate‑containing meal 
in healthy subjects was found to be decreased by exog‑
enous GLP‑1 in healthy subjects, because of slower gastric 
emptying causing lower post‑load blood glucose levels.45 
In elderly T2DM patients whose OHA had been discon‑
tinued, continuous GLP‑1 infusion for 12 weeks enhanced 
postprandial insulin secretion, and insulin‑mediated glucose 
Table 1 Actions of incretins on the defects in glucose handling, β-cell function, and energy intake in type 2 diabetes patients
Defects in type 2 diabetes Actions of incretins
impaired glucose-stimulated insulin secretion and  
lack of postprandial biphasic response
Restoration of glucose‑dependent insulinotropic effect and first‑phase response
Hyperglucagonemia Suppression of glucagon secretion
Defective hypoglycemia counter-regulation Glucagon secretion, and loss of insulinotropic effect, when plasma glucose is low
Reduced β-cell mass and insulin content increased synthesis of proinsulin, possible increased β-cell mass or differentiation 
of islet precursor cells into β-cells
Accelerated β-cell apoptosis Possible inhibition of toxin-induced β-cell apoptosis
Normal, retarded or accelerated gastric emptying Slowing of gastric emptying
Hypercaloric energy intake, obesity Suppression of appetite/increased satiety, weight lossTherapeutics and Clinical Risk Management 2009:5 686
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disposal, while maintaining satisfactory glycemic control 
(HbA1c ∼7%).46 In another study,47 sustained improvements 
of insulin secretory capacity and insulin sensitivity were 
accompanied by reductions in HbA1c (∼1%) and weight 
(∼2 kg) with supraphysiological (60 to 70 pmol/L) levels 
of GLP‑1 maintained by 6 weeks of subcutaneous infusion. 
Accordingly, the mechanisms by which exogenous GLP‑1 
reduces postprandial glycemia in both healthy subjects and 
T2DM patients include delaying the entry of nutrients into the 
intestine, as well as increasing the insulin, and suppressing 
the glucagon, response to carbohydrate.
In addition to glycemic control, GLP‑1 may have ben‑
eficial cardiovascular effects. Continuous GLP‑1 infusion 
increases myocardial insulin sensitivity and glucose uptake, 
leading to improved left ventricular (LV) contractility, 
as evidenced by a significant rise in LV ejection fraction 
from ∼30% to 40% in both non‑diabetic and diabetic 
patients after acute myocardial infarction,48 and in patients 
with chronic heart failure.49 Perioperative (12 hours before 
and 48 hours after) GLP‑1 infusion in T2DM patients who 
underwent coronary artery bypass grafting not only improved 
glycemic control, but also reduced hospital mortality and 
requirements for inotropic agents.50 A shorter, purely post‑
operative (12 hours after), period of intravenous GLP‑1 
also improved glycemic control and reduced the need for 
inotropic support in a group of T2DM patients after bypass 
surgery.51 Endothelial function is improved by GLP‑1, which 
induces vasodilation in coronary artery grafts of patients 
with ischemic heart disease,52 and increases flow‑mediated 
dilatation in brachial arteries of healthy humans.53 GLP‑1 
is thought to act by both GLP‑1 receptor‑dependent and‑
independent pathways, via its metabolites GLP‑1 (7–36) and 
GLP‑1 (9–36) respectively.54
The encouraging outcomes of studies of GLP‑1 admin‑
istration in T2DM have led to the development of drugs that 
enhance GLP‑1 activity: synthetic long‑acting agonists (such 
as exenatide and liraglutide) that are resistant to degradation 
by DPP‑IV and could thus be administered less frequently, 
and inhibitors of DPP‑IV (such as sitagliptin and vildagliptin) 
that increase endogenous GLP‑1 levels. GLP‑1 agonists and 
DPP‑IV inhibitors are discussed in the following sections.
GLP‑1 agonists
exenatide (synthetic exendin-4) 
and exenatide LAR
Exenatide (Byetta®; Eli Lilly and Co.), an injectable GLP‑1 
receptor agonist, was approved by the US Food and Drug 
Administration (FDA) in 2005 as an adjunct therapy for 
T2DM patients who fail to achieve satisfactory glycemic con‑
trol on metformin in combination with SU and/or TZD, and is 
currently available in the United States, the European Union, 
Australia and several Asian countries. It was developed from 
exendin‑4, found in the saliva of the gila monster lizard,55 
has approximately 50% homology with human GLP‑1, 
but binds more avidly to GLP‑1 receptors, and is resistant 
to degradation by DPP‑4, thus prolonging its duration of 
effect.56 Exenatide is administered twice daily in a dose of 
5 or 10 µg by subcutaneous injection. Reductions in fasting 
and postprandial glucose are mediated by the combined 
effects of glucose‑dependent insulin secretion, suppression of 
glucagon release, and, in the case of postprandial glycemia, 
perhaps predominantly by the slowing of gastric emptying 
and the resulting delayed entry of nutrients into the small 
intestine.57 Acutely, postprandial glucose levels are decreased 
by up to 75% primarily as a result of the substantial, and 
dose‑dependent, slowing of gastric emptying,58 associated 
with a reduction in plasma insulin levels in absolute terms. 
As a result of delayed gastric emptying (the magnitude 
of which differs substantially between individuals), oral 
medication such as contraceptive pills and antibiotics, whose 
efficacy depends on reaching a threshold concentration, are 
best taken at least an hour before exenatide.59 As exenatide 
is primarily cleared by the kidneys, its use is contraindicated 
in patients with end‑stage renal disease.59
Exenatide has been studied as monotherapy, as well as 
in combination with OHAs. In drug‑naïve T2DM patients, 
a dose of 5 µg twice daily (bid), for 4 weeks, followed 
by 10 µg bid for 26 weeks, reduced mean HbA1c (∼1%), 
fasting glucose (∼1 mmol/L,) and weight (∼3 kg), compared 
to non‑significant reductions with placebo.60 Three large, 
randomized, placebo‑controlled, 30‑week trials compared 
the efficacy and tolerability of exenatide 5 or 10 µg bid 
added to metformin,61 sulfonylureas (SU),62 or both,63 in 
T2DM patients with HbA1c 7.5% to 11% and body mass 
index (BMI) 27 to 45 kg/m2, who were inadequately 
controlled on metformin and/or SU. Exenatide 10 µg bid 
reduced HbA1c by 0.8% to 1.0%, 40% of patients achieving 
a HbA1c  7.0%. The weighted mean decrease in HbA1c in 
these studies was 1.0% (CI 0.8% to 1.2%)64, equating to a 
4.2 odds ratio for attaining HbA1c  7.0%, and reductions 
of ∼1.5 mmol/L in fasting glucose and 1.4 kg in body 
weight. An open‑label 52‑week extension of these trials in 
overweight patients indicated that exenatide has a sustained 
beneficial effect on glycemic control: ∼50% of these patients 
achieved HbA1c  7% and mean weight loss was 4.4 kg Therapeutics and Clinical Risk Management 2009:5 687
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after 82 weeks.65 Pancreatic β‑cell function (assessed by the 
homeostasis model of assessment, HOMA) improved by 20% 
in T2DM patients on a TZD, with or without metformin, who 
were treated with exenatide, when compared to patients in 
whom placebo was added to their existing OHA;66 however, 
this may reflect the improvement in glycemic control per se, 
rather than an absolute increase in β‑cell mass or longevity. 
In these trials, the magnitude of the reduction in HbA1c with 
exenatide was greater with higher pre‑treatment HbA1c,64 
indicating greater benefits of GLP‑1 agonist treatment in 
patients with relatively worse glycemic control. Twice‑daily 
exenatide was also compared with insulin in an open‑label 
trial of patients with long‑standing T2DM suboptimally 
controlled on stable doses of OHA. Patients on exenatide and 
insulin glargine had comparable decreases in HbA1c (∼1%), 
with lower postprandial excursions in the exenatide group,67 
and greater reduction in fasting and ‘premeal’ glucose in the 
insulin‑treated group. In addition, body weight decreased 
(–2.3 kg) progressively over 26 weeks in patients treated with 
exenatide, with significant loss (–1.9 kg) even in those who 
did not report nausea, and increased (1.8 kg) in patients on 
insulin. In a cross‑over trial, HbA1c fell by about 1.4% with 
both treatments,68 while postprandial excursions were less 
and weight loss occurred with exenatide treatment. Similar 
trends were seen in another study comparing exenatide 
with premixed biphasic insulin aspart in overweight T2DM 
patients who were suboptimally controlled with OHA.69 
Hence, it appears that exenatide is non‑inferior to insulin for 
glycemic control, and has the advantage of causing weight 
loss in obese T2DM patients.
Exenatide LAR, a long‑acting release form, has been 
developed for once‑weekly subcutaneous injection, but has 
not yet been marketed. In a 15‑week trial of T2DM patients 
suboptimally controlled by metformin or diet and exercise, 
exenatide LAR 2 mg/week reduced mean HbA1c by 1.7%, 
fasting glucose by ∼2 mmol/L, and weight by 3.8 kg.70 
In T2DM patients with suboptimal control on diet and exer‑
cise or 1 OHA, this dose of exenatide LAR resulted in 
comparable reductions in HbA1c, fasting glucose and weight 
after 30 weeks of treatment, with a reduced incidence and 
severity of nausea and other GI AEs than, exenatide 10 µg 
bid.71 Exenatide LAR may produce smaller effects in post‑
prandial glucose excursions, perhaps because inhibition of 
gastric emptying is less (the latter has hitherto only been 
assessed using the kinetics of paracetamol absorption), than 
twice‑daily exenatide. This needs to be explored more fully, 
but may suggest that continuous GLP‑1 receptor activation 
slows gastric emptying less than repeated, acute exposure to 
GLP‑1 agonists, and may also mitigate the GI AEs. Exenatide 
LAR may potentially be a useful alternative for patients who 
are less tolerant of frequent injections, though its place in 
therapy remains to be determined.
Liraglutide
Liraglutide has 97% homology with GLP‑1, and is longer‑
acting than exenatide because of an attached free fatty acid 
derivative that increases non‑covalent binding to albumin, 
and renders it more resistant to DPP‑4 degradation, which 
slows renal clearance and absorption from the subcutane‑
ous injection site.72 Its half‑life is ∼12 hours, allowing it 
to be administered once daily;73 while its onset of action is 
slower than exenatide, it is effective and well tolerated in 
doses of up to 1.9 mg/day.74,75 Liraglutide has recently been 
recommended for marketing authorization (under the trade 
name Victoza®; Novo Nordisk) as combination treatment 
with metformin and/or SU, or metformin ± TZD in T2DM 
patients with suboptimal control, by the Committee for 
Medicinal Products for Human Use (CHMP) under the 
European Medicines Agency (EMEA), with final market‑
ing authorization expected from the European Commission 
by June 2009.76 Liraglutide improves glycemic control and 
increases insulin secretion in response to carbohydrate 
loads.68–73 Effects on gastric emptying or appetite have not 
been observed thus far, despite its efficacy in reducing body 
weight. Liraglutide monotherapy for 14 weeks reduced 
HbA1c, fasting glucose, and weight, and increased the propor‑
tion of subjects achieving HbA1c  7% compared to placebo, 
in a phase 2 randomized double‑blind trial of patients with 
suboptimal control on diet or 1 OHA,74 the greatest effects 
being seen with a daily dose of 1.9 mg. Phase 3 trials in the 
Liraglutide Effect and Action in Diabetes (LEAD) program 
investigated the effects of liraglutide as monotherapy, or in 
combination with various OHAs. A 52‑week monotherapy 
trial (LEAD‑3) demonstrated that liraglutide 1.2 mg and 
1.8 mg daily led to greater reductions in HbA1c and fasting 
glucose than glimepiride 8 mg daily.77 In addition, body 
weight decreased significantly by ∼2 kg in patients on lira‑
glutide compared to a mean gain of 1 kg on glimepiride, 
and the incidence of minor hypoglycemia in the liraglu‑
tide group was ∼10%, compared to 24% of patients on 
glimepiride. A 26‑week comparison of the efficacy and 
safety of liraglutide, glimepiride, and placebo, in combina‑
tion with metformin, found that liraglutide resulted in a 
comparative improvement in glycemic control, with weight 
loss and a lower incidence of  hypoglycemia.78 A 26‑week, 
double‑blind, placebo‑controlled study (LEAD‑4 Met + TZD) Therapeutics and Clinical Risk Management 2009:5 688
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demonstrated that liraglutide when combined with metformin 
and rosiglitazone was effective for glycemic control.79 
Another 26‑week study found that when either liraglutide, 
placebo, or rosiglitazone was added to glimepiride, 
liraglutide produced the greatest reductions in HbA1c and 
fasting glucose80 and adding liraglutide to glimepiride 
stabilized body weight. The beneficial effect of liraglutide on 
body weight was also seen in a trial of patients on metformin 
and glimepiride, which compared the addition of liraglutide 
(mean weight loss of 1.8 kg) with that of insulin glargine 
(weight gain of 1.6 kg),81 Liraglutide‑induced weight loss 
reflected a reduction in visceral and subcutaneous fat mass, 
and lean mass increased slightly.82 Markers of β‑cell function, 
such as the proinsulin:insulin ratio,74 HOMA,80 and first‑ and 
second‑phase insulin responses during arginine‑stimulated 
hyperglycemia,83 were also improved by liraglutide. Hence, 
like exenatide, liraglutide is effective in improving and main‑
taining glycemic control as monotherapy or in combination 
with OHA, and in reducing body weight, with the advan‑
tage over twice‑daily exenatide of requiring less frequent 
injections.
Safety and tolerability of GLP-1 agonists
Hypoglycemia is clearly less common with the use of GLP‑1 
agonists than with SU or insulin, presumably reflecting the 
glucose‑dependent effects of the former on endogenous 
insulin secretion. The frequency of minor hypoglycemic 
episodes (about 5%) was comparable to placebo in studies of 
exenatide with metformin as the background therapy, though 
the incidence of hypoglycemia increased when exenatide 
improved glycemic control in conjunction with SU, and 
decreased in tandem with reduction in SU dose.64 Severe 
hypoglycemia was rare when exenatide was combined with 
either metformin or TZDs.61,63,66 The incidence of severe 
hypoglycemia was about 1.5% in the exenatide/glargine 
parallel‑group comparative study,67 but none of the episodes 
was severe, required medical attention or necessitated with‑
drawal of treatment. Minor hypoglycemia has been reported 
in ∼10% of patients taking liraglutide as monotherapy74 
or in combination with metformin and/or TZD,79 though 
the incidence is increased to ∼25% when liraglutide is 
added to SU.78,80
The adverse effects of GLP‑1 agonists are chiefly 
gastrointestinal.58–86 Nausea is the most common with both 
the short‑acting and LAR formulations of exenatide,58–68 
with mild to moderate self‑reported nausea in ∼35% of 
patients on exenatide 5 µg bid and up to half of the patients 
receiving 10 µg bid.84 In most patients the frequency, 
and severity, peaks in the first 8 weeks of treatment and 
decreases thereafter,64,66 and is likely to be a central GLP‑1 
effect, unrelated to the slowing of gastric emptying.84 
Other GI AEs, such as diarrhea and constipation, are less 
common, and are also usually transient and mild. In clinical 
trials, treatment discontinuation because of GI AEs (nausea, 
vomiting, diarrhea, anorexia, abdominal pain) occurred in 
about 5% of patients. The risk of exenatide‑induced nausea 
can apparently be minimized by progressive escalation in 
dosage.85 The frequency of nausea may be less in patients 
on exenatide LAR.70,71 Liraglutide is also associated with GI 
AEs, which are dose‑dependent, the most common being 
transient mild‑to‑moderate nausea, which occurs in 5% to 
15% of patients.73–77 A patient‑reported evaluation of GI AEs 
using the Gastrointestinal System Rating Scale (GSRS),84 as 
part of a 14‑week phase 2 trial,74 indicated that GI symptoms 
are not usually severe (maximum 2 on a 7‑point scale), and 
occur mainly in the first 2 weeks of treatment, returning to 
baseline thereafter. In a 26‑week study of T2DM patients with 
suboptimal glycemic control on OHA, once‑daily liraglutide 
was associated with less persistent nausea than twice‑daily 
exenatide, which may be attributable to smaller fluctuations 
in concentration of the GLP‑1 receptor agonist.86
Anti‑exenatide antibodies are evident in about half to 
two‑thirds of patients on exenatide,64 or exenatide LAR,70 
but do not appear to affect either glycemic control or adverse 
events. A higher prevalence of injection‑site discomfort and 
anti‑exenatide antibodies were seen in patients on the LAR 
form. Anti‑liraglutide antibodies have been detected in ∼10% 
of patients, but, again, do not appear to have adverse effects, 
or influence glycemic control.81
GLP-1 agonists in development
New GLP‑1 agonists have demonstrated improvement in 
fasting and postprandial glucose control in phase III trials, 
with apparently fewer GI AEs than currently marketed com‑
pounds. Albiglutide, a DPP‑4‑resistant GLP‑1 analog which 
is administered weekly, reduced fasting and postprandial 
glucose levels without causing hypoglycemia in healthy 
subjects87 and T2DM patients.88 A dose of 32 mg reduced 
24‑hour mean weighted glucose by 35 mg/dL (∼2 mmol/L) 
at day 2 and 56 mg/dL (∼3 mmol/L) at day 9 after treatment 
in T2DM subjects. Of note, the frequency and severity of GI 
AEs of albiglutide were comparable to placebo. Taspoglutide, 
another once‑weekly GLP‑1 agonist, reduced HbA1c (∼0.9% 
to 1.2%), as well as fasting and postprandial glucose levels 
at doses of 10 or 20 mg in T2DM, in combination with met‑
formin for 8 weeks, with a low incidence of hypoglycemia.89 Therapeutics and Clinical Risk Management 2009:5 689
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Weight loss was also significant, especially in the group 
receiving 20 mg/week (–2.8 kg).
DPP‑4 inhibitors
Prevention of GLP‑1 degradation by pharmacological DPP‑4 
inhibition in pigs,90 and genetic inactivation in DPP‑4 knock‑
out mice,91 increase endogenous total GLP‑1 levels, leading 
to increased insulin secretion and reduced fasting and post‑
prandial glucose concentrations. These findings have led to 
the development of once‑daily, orally‑active DPP‑4 inhibitors 
to increase the incretin effect. DPP‑4 activity is reduced by 
almost 100% within 15 to 30 minutes of oral administra‑
tion of the DPP‑4 inhibitors sitagliptin or vildagliptin, 
producing a 2‑fold increase in mean active GLP‑1 levels 
(to 15 to 25 pmol/L), with a duration of inhibition in excess of 
16 hours because of initial rapid binding to DPP‑4, followed 
by a slow phase of tight binding,92 so that effects persist for 
24 hours after administration of a single dose of sitagliptin93 
and vildagliptin.94 DPP‑4 inhibition increases GLP‑1 and GIP 
levels by 2‑ to 3‑fold, while reducing glucagon,92 although 
the magnitude of the rise in GLP‑1 is dependent on the type 
of nutrient ingested. The pharmacokinetics of sitagliptin 
and vildagliptin are not affected by age, gender, ethnicity or 
body mass index, and no significant drug interactions have 
hitherto been noted.95
Sitagliptin
Sitagliptin (Januvia®; Merck and Co, Inc.) was approved for 
use in a dose of 100 mg once daily, by the FDA in 2006 and 
subsequently in the EU, Australia and Asia, for the improve‑
ment of glycemic control in combination with metformin 
and/or a sulfonylurea when diet and exercise plus OHA 
do not result in adequate glycemic control.96 In drug‑naïve 
T2DM patients, sitagliptin monotherapy is more effective 
than placebo in reducing HbA1c (by up to 1%) and fasting 
glucose (by up to 18 mg/dL).97 Greater benefits in glycemic 
control were seen with sitagliptin 100 mg daily, compared 
to placebo, over a period of 24 weeks in T2DM patients 
already on metformin98,99 and pioglitazone,100 and when 
added to sulfonylureas (with or without metformin).101 It was 
non‑inferior to glipizide when added to ongoing metformin 
therapy.102 Metformin stimulates GLP‑1 release, increasing 
both active and total GLP‑1 levels by 2‑fold, but does not act 
as a DPP‑4 inhibitor, and, accordingly, has a synergistic effect 
with sitagliptin, to increase both active GLP‑1 (∼4‑fold).103 
A fixed‑dose combination of sitagliptin and metformin 
(Janumet®; Merck and Co, Inc.) has recently been developed. 
An improvement in β‑cell function has been suggested by a 
reduction in the proinsulin ratio and increase in insulin levels 
with sitagliptin, compared to placebo.97,98,100 The effect of 
sitagliptin on gastric emptying has not been reported. Unlike 
GLP‑1 agonists, sitagliptin is not associated with changes 
in body weight.97–102 Sitagliptin is thus a useful add‑on 
therapy to OHA in T2DM patients who are not overweight, 
especially those with suboptimal control on maximum doses 
of metformin. Dose adjustment of sitagliptin is recommended 
in patients with renal insufficiency.104
vildagliptin
Vildagliptin (Galvus®; Novartis) was approved in the EU in 
2008, for use in combination with metformin and/or TZD 
(50 mg twice daily), or with an SU (50 mg once daily), 
and is pending approval by the FDA.105 Vildagliptin mono‑
therapy was shown to be superior to placebo in reducing 
HbA1c (by 0.4% to 0.8%), fasting (by ∼10 to 20 mg/dL) 
and postprandial glucose,106 and non‑inferior compared to 
rosiglitazone107 in randomized, double‑blinded 24‑week trials. 
The addition of vildagliptin to metformin further improved 
glycemic control (HbA1c reduction 0.5% to 1.2%).108,109 The 
combination of vildagliptin with pioglitazone reduced fasting 
glucose to a greater extent than did vildagliptin or piogli‑
tazone alone,110 and vildagliptin is not inferior to pioglitazone 
when added to metformin.111 Vildagliptin has been shown to 
increase insulin and C‑peptide responses to glucose by up to 
100%,108,112 suggesting improvements in β‑cell function.113 
DPP‑4 inhibition by vildagliptin does not apparently slow 
gastric emptying, possibly due to the relatively modest eleva‑
tion in plasma GLP‑1 levels, compared to administration of 
exogenous GLP‑1 agonists.114
Safety and tolerability of DPP-4 inhibitors
Neither sitagliptin97–102 nor vildagliptin106–114 appear to increase 
the risk of hypoglycemia when used as monotherapy, or in 
combination with metformin or TZD, though the incidence 
of mild‑moderate hypoglycemia was increased by approxi‑
mately 2‑fold to ∼4% to 5% when sitagliptin was added to 
SU.101,102 DPP‑4 inhibitors have not been associated with 
significant GI AEs, and appear to be safe and well‑tolerated in 
patients with moderate to severe renal insufficiency (includ‑
ing those with end‑stage disease on hemodialysis) if doses are 
adjusted according to creatinine clearance.115 An increased 
risk (odds ratio 1.34, 95% CI 1.10 to 1.64) of nasopharyngitis 
and all‑cause infections (sinusitis, viral upper respiratory 
tract infections, urinary tract infections) has been observed 
with the use of sitagliptin,95 and hypersensitivity reactions 
(anaphylaxis, angioedema and exfoliative dermatitis) have Therapeutics and Clinical Risk Management 2009:5 690
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been reported within the first 3 months of sitagliptin therapy,96 
while cases of vildagliptin‑associated severe dermatological 
allergic reactions and elevated liver transaminases, have led 
to a delay in FDA approval.105
DPP-4 inhibitors in development
Alogliptin and saxagliptin are DPP‑4 inhibitors that may be 
available in the near future: alogliptin is currently under FDA 
review, while saxagliptin is under review by the EMEA for 
potential marketing in late 2009. Alogliptin monotherapy 
is reportedly effective in reducing HbA1c, as well as fasting 
and postprandial glucose levels in T2DM patients in doses of 
25 to 400 mg daily.116,117 In randomized, placebo‑controlled, 
double‑blinded 26‑week trials, the addition of alogliptin 
to metformin118 or glyburide119 improved HbA1c and fast‑
ing glucose without an increased incidence of GI AEs or 
hypoglycemia. Alogliptin also improved glycemic control 
and β‑cell function in combination with pioglitazone120 or 
insulin121 in animal models. Saxagliptin reduced HbA1c and 
both fasting and postprandial glucose levels in drug‑naïve 
T2DM patients in a placebo‑controlled, randomized, 
double‑blind study,122 and evidence from ongoing trials 
suggests that it may be effective in combination with 
metformin,123 glyburide124 or TZD.125 Daily doses of alogliptin 
12.5 to 25 mg and saxagliptin 2.5 to 10 mg lower HbA1c 
by ∼1%, which is comparable to sitagliptin and vildagliptin 
in doses of 50 to 100 mg daily, implying greater potency. 
In addition, no adverse effects attributable to disordered 
immune function have been reported to date for alogliptin 
or saxagliptin,126 although it should be recognized that 
most of the clinical data available on the newer DPP‑4 
inhibitors have been published only in abstract form, and 
there is less information available about their safety profiles, 
in comparison with sitagliptin and vildagliptin.
Extraglycemic effects 
of incretin‑based therapies
In addition to improving glycemic control, GLP‑1 agonists 
may have additional beneficial effects on blood pressure 
(BP) and plasma lipids, in part, by effects that are apparently 
independent of weight loss. Exenatide 5 µg bid reduced 
BP by ∼9 mmHg from baseline when added to existing 
antihypertensive therapy and OHA in obese T2DM patients 
during 26 weeks of treatment,127 while mean diastolic and 
systolic BP (in another trial of obese T2DM patients on 
5 to 10 µg bid for 82 weeks128) was reduced by ∼4 mmHg 
and ∼6 mmHg respectively, with the greatest reduction 
seen in patients who lost the most weight. Patients treated 
with exenatide 5 to 10 µg bid for an average of 3.5 years 
demonstrated significant reductions in triglycerides (12%), 
total cholesterol (5%), low‑density lipoprotein (LDL) 
cholesterol (6%), and increases in high‑density lipoprotein 
(HDL) cholesterol (24%);129 again, these beneficial effects 
were related to the magnitude of weight loss. However, 
a recent study using exenatide LAR71 found that the mean 
reductions in systolic BP over 30 weeks (–4.7 mmHg) and 
diastolic BP (–1.7 mmHg) were independent of  body weight. 
In the LEAD studies77–80 liraglutide 1.8 mg daily for 2 weeks 
reduced mean systolic BP by ∼2 to 4.5 mmHg, which was 
also apparently independent of weight loss. Liraglutide was 
found to lower triglyceride (TG) levels in association with 
reductions in weight and HbA1c.74 Other than weight reduc‑
tion, the mechanisms by which GLP‑1 agonists improve BP 
and lipids remain unclear. As discussed previously, GLP‑1 
analogues also have direct beneficial effects on the heart, 
as shown by animal studies. Both exenatide and GLP‑1 
(9–36) improve left ventricular performance and decreased 
infarct size in rat hearts during reperfusion after ischemia.130 
Liraglutide also induces significant infarct shrinkage in an 
ischemia‑reperfusion injury murine heart preparations.131 
In T2DM patients, liraglutide reduces levels of the inflam‑
matory markers plasminogen activator inhibitor 1, B‑type 
natriuretic peptide and high‑sensitivity C‑reactive protein, 
which are associated with increased cardiovascular risk.132
There is also evidence that DPP‑4 inhibitors also have 
beneficial effects on BP and lipids. In non‑diabetic patients 
with moderate hypertension, sitagliptin reduced systolic 
and diastolic BP by ∼2 mmHg, compared to placebo, within 
5 days at doses of 50 to 100 mg daily.133 Sitagliptin also 
reduced plasma TG by 10% to 15% and increased HDL 
by ∼5% in doses of 25 to 100 mg daily as monotherapy 
over 12 weeks in T2DM patients.134 Vildagliptin lowered 
total and LDL cholesterol by ∼10%135 and TG by up to 
15%122 when added to TZD in metformin‑resistant patients. 
Possible mechanisms for the lipid‑lowering effects of  DPP‑4 
inhibitors include reduced production of intestinal TG‑rich 
particles after fat‑rich meals136 and augmentation of lipid 
mobilization and oxidation,137 although the exact mechanisms 
remain unclear.
Table 2 compares GLP‑agonists and DPP‑inhibitors.
Unresolved issues and long-term 
safety of incretin-based therapies
The slowing of gastric emptying induced by exogenous 
GLP‑1 and GLP‑1 agonists may cause concerns over use in 
T2DM patients with gastroparesis. It is now well recognized Therapeutics and Clinical Risk Management 2009:5 691
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that gastric emptying (GE) is delayed in perhaps 30% of 
patients with long‑standing T2DM,32 and correlates poorly 
with the presence and severity of upper GI symptoms.138 
In healthy subjects the magnitude of the slowing of GE 
by exogenous GLP‑1 is sufficient to cause ‘gastroparesis’ 
in ∼50%,45 and in T2DM patients the slowing of GE by 
exenatide is greater when GE is relatively faster.58 It is 
also known that in diabetics with vagal neuropathy, unlike 
healthy subjects, exogenous GLP‑1 fails to relax the proximal 
stomach.139 The implications are that the magnitude of the 
reduction in postprandial glycemia induced by GLP‑1 is 
likely to depend on GE, and that in patients with autonomic 
neuropathy‑associated gastroparesis (whether symptomatic 
or not), any further slowing of gastric emptying is likely to be 
minimal. Both of these hypotheses warrant formal evaluation. 
Patients with symptomatic gastroparesis have been excluded 
from the majority of trials of GLP‑1 agonists – hence, the 
issue of whether these drugs exacerbate, or have no effect 
on symptoms, also remains unresolved.
Post‑marketing cases of acute pancreatitis have rarely been 
reported with exenatide;140 however, T2DM patients have 
a ∼3‑fold increased risk of pancreatitis,141 as well as other risk 
factors for pancreatitis including gallstones, obesity, ethanol 
abuse and severe hypertriglyceridemia. Eight out of the nine 
reported cases of pancreatitis in the LEAD program occurred 
in patients on liraglutide.142 Studies in animals to evaluate this 
issue have hitherto failed to clarify whether there is a causal 
association between pancreatitis and the use of incretin‑based 
therapies. Administration of metformin, sitagliptin, or lira‑
glutide did not increase transcription of genes associated with 
pancreatitis in mice, and GLP‑1 receptor knockout mice did 
not differ from normal mice in the severity of experimentally 
induced pancreatitis when treated with exenatide.143 However, 
treatment with sitagliptin and metformin was associated 
with increased pancreatic ductal turnover, ductal metaplasia, 
and one case of pancreatitis in rats.144
The non‑GI AEs associated with sitagliptin and vilda‑
gliptin may be related to the immunological properties of 
DPP‑4, which is expressed in many tissues, and has numerous 
substrates, including GI hormones, neuropeptides, and 
cytokines.145 As DPP‑4 is known to be involved in immu‑
noregulation as a T‑cell costimulator, and in breakdown of 
cytokines such as bradykinin and interleukin‑2 and ‑1β,146 
inhibition of DPP‑4 may have adverse effects on immune 
function. Indeed, the severity of rheumatoid arthritis has 
been reported to be inversely related to DPP‑4 activity,147 
and DPP‑4 levels are reduced in nasal tissue of patients 
with chronic rhinosinusitis.146 Although DPP‑4 inhibition is 
known to reduce the levels of the cardioprotective GLP‑1 
metabolite GLP‑1 (9–36) which is cleaved from native intact 
GLP‑1, there is hitherto no evidence of  adverse cardiovas‑
cular effects.101–118 As clinical trials involving sitagliptin and 
vildagliptin evaluated use for a maximum of only 52 weeks, 
more long‑term safety data are required, particularly in view 
Table 2 Comparison of GLP-1 agonists and DPP-4 inhibitors
  GLP‑1 agonists DPP‑4 inhibitors
Currently marketed  exenatide (short-acting and long-acting release), liraglutide Sitagliptin, vildagliptin 
Mode of action  GLP-1 receptor agonist, resistant to degradation by DPP-4  inhibits degradation of GLP-1 → increases endogenous 
GLP-1 level 
Usage + metformin ± SU ± TZD  + metformin and/or TZD and/or SU
Administration Subcutaneous injection (pen) Oral (tablet)
Reduction in HbA1c  ∼1% to 1.5% ∼0.5% to 1%
B-cell function  Possibly improved Possibly improved
Extraglycemic benefits  ↓ BP
↓ Cholesterol, LDL, TG, ↑HDL 
↑ Left ventricular function, arterial vasodilation 
(GLP-1 infusion) 
↓ BP (sitagliptin)
↓ Cholesterol, LDL, TG, ↑HDL
Hypoglycemia very low risk very low risk
weight Reduction Neutral
Gi adverse effects  Frequent (∼35% to 50%, dose-dependent and usually 
self-limited)
Uncommon
Gastric emptying  Slowed (greatest effect with exenatide) No effect
Other adverse effects Pancreatitis Nasopharyngitis, upper respiratory tract infection, 
headache; elevated liver enzymes (vildagliptin)
Abbreviations: BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SU, sulfonylureas;   TG, triglycerides;   TZD, thiazolidinediones.Therapeutics and Clinical Risk Management 2009:5 692
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of  the need for chronic treatment in T2DM, and the presence 
of DPP‑4 in multiple organ systems.
Cost‑effectiveness and patient‑
centered outcomes of incretin‑
based therapies
The cost‑effectiveness of exenatide, compared to OHA or 
insulin, has been evaluated in several studies. As add‑on 
therapy to metformin, it is cost‑effective compared to 
pioglitazone and glibenclamide,59 and also as monotherapy 
in drug‑naïve patients compared to metformin alone. 
An analysis, based on data from 314 overweight T2DM 
patients who completed an 82‑week trial of exenatide,65 
projected that 30 years of treatment with exenatide added 
to OHA would be cost‑effective in comparison to a hypo‑
thetical placebo arm,148 in terms of improvements in clinical 
outcomes (glycemic control, weight, BP, and lipids) with 
concomitant reductions in the risk of micro‑ and macrovas‑
cular complications, increased life expectancy, and improved 
quality of life. These were associated with incremental 
cost‑effectiveness ratios (ICER) of US$35,571/life‑years 
gained, and US$36,133/quality‑adjusted life‑year, below the 
threshold ICER of US$50,000. Using data from the same 
cohort, a study projected models of long‑term complications, 
life expectancy, quality‑adjusted life expectancy, and direct 
medical costs of patients on exenatide versus those on insulin 
glargine in the United Kingdom (UK),149 and concluded that 
exenatide was associated with a lower cumulative incidence 
of most cardiovascular (CVD) complications, including 
CVD‑related death, and was more cost‑effective than 
glargine. However, this study based its analyses on estimated 
costs of exenatide which ranged from 20% to 100% of the 
US price (US$161/28 days). Another UK study, which used 
the actual UK National Health System price of exenatide 
(∼£68/28 days), rather than an estimated cost, found that 
exenatide was less cost‑effective than glargine in a 40‑year 
projection.150 It is evident that the cost‑effectiveness of exena‑
tide in relation to insulin glargine is highly dependent on the 
relative prices of these medications, which vary substantially 
between countries.
Patient‑reported measures, such as quality of life and 
treatment satisfaction, have also been analyzed, using data 
from a 26‑week randomized, open‑label study comparing 
exenatide to insulin glargine in T2DM patients with suboptimal 
glycemic control on metformin and sulfonylurea.67 This anal‑
ysis included 228 patients on exenatide and 227 on insulin, 
with outcomes measured by 5 scales: 1) Diabetes Symptom 
Checklist (frequency and perceived discomfort of physical 
and psychological symptoms associated with diabetes); 
2) Diabetes Treatment Flexibility Scale (focusing on patient 
choices in meals and daily activities); 3) Diabetes Treatment 
Satisfaction Questionnaire (satisfaction with current treat‑
ment regimen); 4) EuroQol‑EQ5D (overall health status); 
and 5) vitality scale of the SF‑36 (energy level and fatigue). 
Both exenatide and insulin groups showed significant 
improvement from baseline in symptoms, satisfaction with 
treatment, overall health status, and energy levels.151 The 
authors noted that although exenatide was associated with 
GI AEs and increased frequency of injections, these did not 
result in less patient satisfaction, which they attributed to 
the benefits of weight loss in this treatment group. Hence, 
the benefits of exenatide therefore appear to outweigh adverse 
effects, weight loss in particular conferring an advantage 
over insulin. At present, there are no cost‑benefit analyses 
available for liraglutide.
In relation to the DPP‑4 inhibitors, a cost‑effectiveness 
analysis compared the addition of sitagliptin, rosiglitazone 
or SU to metformin in patients with HbA1c  6.5%.152 Local 
health surveys in Austria, Finland, Portugal, Scotland, Spain, 
and Sweden were used to generate average patient profiles for 
the analysis, using data on clinical and adverse effects from 
two recent trials of sitagliptin.102,153 Adding sitagliptin was 
found to be a more cost‑effective alternative to the addition 
of rosiglitazone or an SU, incremental cost‑effectiveness 
ratio values ranging from  5949/QALY to  20 350/QALY, 
depending on the individual country. However, these studies 
may not be generalizable to countries outside the EU, because 
of differences in health care costs and prices of medication. 
Analysis of the cost‑effectiveness of vildagliptin is not cur‑
rently available.
Given the comparable outcomes of the use of GLP‑1 
agonists and DPP‑4 inhibitors in T2DM for many parameters, 
their cost‑effectiveness is an important issue. An analysis com‑
pared estimated six‑month total, and diabetes‑related, medical 
costs among 2482 patients on sitagliptin, with 1885 patients 
on exenatide, in the US.154 Exenatide was associated with 
lower total 6‑month direct medical costs (US$9340 vs 
US$9995), despite some component costs being higher with 
exenatide, ie, those associated with diabetes‑related drugs, 
and diabetes‑related medical care including emergency room 
attendance. Sitagliptin was associated with higher outpatient 
costs. This study concluded that use of the GLP‑1 agonist 
was associated with higher diabetes‑related costs, but lower 
total medical costs than the DPP‑4 inhibitor; however, as with 
comparisons of  incretin therapies with conventional injectable Therapeutics and Clinical Risk Management 2009:5 693
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and oral medications, the results of this cost‑benefit analysis 
cannot be extrapolated to outside the US.
The place of incretin‑based 
therapies in the treatment of   T2DM 
and impaired glucose tolerance
The American Association of Clinical Endocrinologists 
(AACE) currently advocates DPP‑4 inhibitor monotherapy 
for T2DM patients with HbA1c 6% to 7%, or in combina‑
tion with metformin or TZD if target HbA1c (6.5%) is not 
achieved, and adding a GLP‑1 agonist to SU, metformin, 
and/or TZD in patients who do not achieve target HbA1c.155 
In contrast, the American Diabetes Association (ADA) 
and the European Association for the Study of Diabetes 
(EASD) did not recommend, in their combined consensus 
statements on standards of medical care in diabetes156 and 
initiation and adjustment of treatment in T2DM,4 either 
GLP‑1 agonists or DPP‑4 inhibitors as first‑ or second‑tier 
treatments, despite acknowledging the weight‑lowering 
effect of exenatide, and the utility of exenatide and sita‑
gliptin for improved postprandial glycemic control with 
an associated low risk of hypoglycemia. It should be rec‑
ognized that selected groups of patients may benefit from 
early, or even first‑line, use of incretin‑based therapies. The 
weight‑lowering effect of GLP‑1 agonists is beneficial in 
the overweight and obese, especially since many add‑on 
therapies (sulfonylurea, TZD and insulin) promote weight 
gain. As discussed, trials using exenatide reported a 
dose‑dependent reduction in body weight by up to 4.5 kg 
in at least 30 weeks.55–65 
GLP‑1 agonists may also have a role in the management 
of critically ill patients with T2DM, in whom both hypergly‑
cemia and hypoglycemia are risk factors for a poor outcome. 
GLP‑1 infusion appears to reduce plasma glucose signifi‑
cantly in association with increased insulin and suppressed 
glucagon concentrations, without the risk of hypoglycemia in 
severely ill patients who were hyperglycemic while receiving 
total parenteral nutrition,157 as well as in fasted diabetic 
patients who had undergone major surgery.158 More recently, 
GLP‑1 infusion has been shown to markedly attenuate the 
glycemic response to enteral nutrition (arguably the preferred 
route of nutritional support) in non‑diabetic critically ill 
patients, reflecting its insulinotropic and glucagonostatic 
properties.159 These observations suggest that GLP‑1 and/or 
its agonists have a potential role in the management of hyper‑
glycemia in the critically ill, without the attendant risks of 
insulin‑induced hypoglycemia. The latter were emphasized 
by the results of the NICE‑SUGAR study, in which the use 
of insulin infusions to achieve target blood glucose 4.5 to 
6.0 mmol/L was shown to increase both hypoglycemia and 
mortality in critically ill patients.160
Although DPP‑4 inhibitors are weight‑neutral and do 
not significantly reduce appetite, their lack of GI side effects 
compared to GLP‑1 agonists and metformin, and low risk 
of hypoglycemia, render them especially suitable for the 
management of T2DM in older patients, in whom the poly‑
pharmacy often required for glycemic control is accompanied 
by increased risks of hypoglycemia and other adverse effects 
due to age‑related changes in drug metabolism, reduced 
energy intake, and comorbidities such as cardiovascular and 
renal impairment. In particular, sulfonylureas are associated 
with a high risk of hypoglycemia accounting for substantial 
morbidity and health‑care costs in this group.161 Studies 
of sitagliptin97,98,162 and vildagliptin106,107,111,163 including 
subjects 65 years of age, and patients with moderately 
severe hepatic164 and renal165 impairment, suggest that the 
DPP‑4 inhibitors are as effective (HbA1c reduction ∼1%) and 
well‑tolerated as in younger patients. The DPP‑4 inhibitors 
were also associated with a low incidence (∼1%) of severe 
hypoglycemia, and GI and other adverse events such as 
peripheral edema (2% to 10%).
Conclusions
Despite the relatively recent advent of GLP‑1 agonists 
and DPP‑4 inhibitors, evidence has rapidly accumulated 
to support their efficacy and safety in the management of 
T2DM, as well as their potential for improving cardiovascular 
and β‑cell function. The low risk of inducing hypoglycemia, 
and beneficial or neutral effects on body weight, render 
them attractive alternatives to insulin secretagogues and 
insulin as add‑on therapy to metformin, or even as first‑line 
therapy in selected groups of patients, especially in the over‑
weight and the elderly. Incretin‑based medications are likely 
to be increasingly at the forefront of therapy of T2DM in the 
new millennium.
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